Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Clinical trial NCT04278859 · COMPLETED
Trial details
- NCT number
- NCT04278859
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-28
- Primary completion
- 2023-07-13
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.